Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review
Schizophrenia spectrum disorders (SSD) are traditionally diagnosed and categorized through clinical assessment, owing to their complex heterogeneity and an insufficient understanding of their underlying pathology. However, disease progression and accurate clinical diagnosis become problematic when d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.885904/full |
| _version_ | 1818240211575898112 |
|---|---|
| author | Timothy A. Couttas Beverly Jieu Cathrin Rohleder Cathrin Rohleder F. Markus Leweke F. Markus Leweke |
| author_facet | Timothy A. Couttas Beverly Jieu Cathrin Rohleder Cathrin Rohleder F. Markus Leweke F. Markus Leweke |
| author_sort | Timothy A. Couttas |
| collection | DOAJ |
| description | Schizophrenia spectrum disorders (SSD) are traditionally diagnosed and categorized through clinical assessment, owing to their complex heterogeneity and an insufficient understanding of their underlying pathology. However, disease progression and accurate clinical diagnosis become problematic when differentiating shared aspects amongst mental health conditions. Hence, there is a need for widely accessible biomarkers to identify and track the neurobiological and pathophysiological development of mental health conditions, including SSD. High-throughput omics applications involving the use of liquid chromatography-mass spectrometry (LC-MS) are driving a surge in biological data generation, providing systems-level insight into physiological and pathogenic conditions. Lipidomics is an emerging subset of metabolomics, largely underexplored amongst the omics systems. Lipid profiles in the brain are highly enriched with well-established functions, including maintenance, support, and signal transduction of neuronal signaling pathways, making them a prospective and exciting source of biological material for neuropsychiatric research. Importantly, changes in the lipid composition of the brain appear to extend into the periphery, as there is evidence that circulating lipid alterations correlate with alterations of psychiatric condition(s). The relative accessibility of fluid lipids offers a unique source to acquire a lipidomic “footprint” of molecular changes, which may support reliable diagnostics even at early disease stages, prediction of treatment response and monitoring of treatment success (theranostics). Here, we summarize the latest fluid lipidomics discoveries in SSD-related research, examining the latest strategies to integrate information into multi-systems overviews that generate new perspectives of SSD-related psychosis identification, development, and treatment. |
| first_indexed | 2024-12-12T13:09:50Z |
| format | Article |
| id | doaj.art-8e21308dadfb483591291d8ac2f463ca |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-12T13:09:50Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-8e21308dadfb483591291d8ac2f463ca2022-12-22T00:23:33ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402022-05-011310.3389/fpsyt.2022.885904885904Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative ReviewTimothy A. Couttas0Beverly Jieu1Cathrin Rohleder2Cathrin Rohleder3F. Markus Leweke4F. Markus Leweke5Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, AustraliaBrain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, AustraliaBrain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, AustraliaDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, GermanyBrain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, AustraliaDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, GermanySchizophrenia spectrum disorders (SSD) are traditionally diagnosed and categorized through clinical assessment, owing to their complex heterogeneity and an insufficient understanding of their underlying pathology. However, disease progression and accurate clinical diagnosis become problematic when differentiating shared aspects amongst mental health conditions. Hence, there is a need for widely accessible biomarkers to identify and track the neurobiological and pathophysiological development of mental health conditions, including SSD. High-throughput omics applications involving the use of liquid chromatography-mass spectrometry (LC-MS) are driving a surge in biological data generation, providing systems-level insight into physiological and pathogenic conditions. Lipidomics is an emerging subset of metabolomics, largely underexplored amongst the omics systems. Lipid profiles in the brain are highly enriched with well-established functions, including maintenance, support, and signal transduction of neuronal signaling pathways, making them a prospective and exciting source of biological material for neuropsychiatric research. Importantly, changes in the lipid composition of the brain appear to extend into the periphery, as there is evidence that circulating lipid alterations correlate with alterations of psychiatric condition(s). The relative accessibility of fluid lipids offers a unique source to acquire a lipidomic “footprint” of molecular changes, which may support reliable diagnostics even at early disease stages, prediction of treatment response and monitoring of treatment success (theranostics). Here, we summarize the latest fluid lipidomics discoveries in SSD-related research, examining the latest strategies to integrate information into multi-systems overviews that generate new perspectives of SSD-related psychosis identification, development, and treatment.https://www.frontiersin.org/articles/10.3389/fpsyt.2022.885904/fullpsychosisfirst-episode psychosis (FEP)clinically high risk patientslipidomicsmetabolomicsLC-MS/MS |
| spellingShingle | Timothy A. Couttas Beverly Jieu Cathrin Rohleder Cathrin Rohleder F. Markus Leweke F. Markus Leweke Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review Frontiers in Psychiatry psychosis first-episode psychosis (FEP) clinically high risk patients lipidomics metabolomics LC-MS/MS |
| title | Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review |
| title_full | Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review |
| title_fullStr | Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review |
| title_full_unstemmed | Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review |
| title_short | Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review |
| title_sort | current state of fluid lipid biomarkers for personalized diagnostics and therapeutics in schizophrenia spectrum disorders and related psychoses a narrative review |
| topic | psychosis first-episode psychosis (FEP) clinically high risk patients lipidomics metabolomics LC-MS/MS |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.885904/full |
| work_keys_str_mv | AT timothyacouttas currentstateoffluidlipidbiomarkersforpersonalizeddiagnosticsandtherapeuticsinschizophreniaspectrumdisordersandrelatedpsychosesanarrativereview AT beverlyjieu currentstateoffluidlipidbiomarkersforpersonalizeddiagnosticsandtherapeuticsinschizophreniaspectrumdisordersandrelatedpsychosesanarrativereview AT cathrinrohleder currentstateoffluidlipidbiomarkersforpersonalizeddiagnosticsandtherapeuticsinschizophreniaspectrumdisordersandrelatedpsychosesanarrativereview AT cathrinrohleder currentstateoffluidlipidbiomarkersforpersonalizeddiagnosticsandtherapeuticsinschizophreniaspectrumdisordersandrelatedpsychosesanarrativereview AT fmarkusleweke currentstateoffluidlipidbiomarkersforpersonalizeddiagnosticsandtherapeuticsinschizophreniaspectrumdisordersandrelatedpsychosesanarrativereview AT fmarkusleweke currentstateoffluidlipidbiomarkersforpersonalizeddiagnosticsandtherapeuticsinschizophreniaspectrumdisordersandrelatedpsychosesanarrativereview |